ADC Biotechnology Ltd specializes in the development of innovative antibody-drug conjugates (ADCs) aimed at treating cancer. Based in St Asaph, United Kingdom, the company has developed a patented Lock-Release technology that streamlines the purification process for ADCs, significantly reducing the number of steps and associated risks in drug production. In addition to its proprietary technology, ADC Biotechnology offers consultancy and research and development services to support drug developers and manufacturers in overcoming challenges related to conjugation processes. Since its establishment in 2010, the company has focused on delivering faster and more cost-effective solutions in the oncology field, facilitating the advancement of targeted therapies for cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.